Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022

Rhea-AI Summary

Evofem Biosciences (Nasdaq: EVFM) will host a conference call on August 4, 2022, at 5:00 p.m. ET to discuss its second-quarter financial results and business highlights. Investors can join the call by dialing (800) 285-6670 for U.S. participants or (713) 481-1320 for international participants. The call will also be available via a live webcast at evofeminvestorroom.com. The company specializes in women's sexual and reproductive health, with Phexxi® as its first FDA-approved product, expected to report clinical trial data this fall.

-- Conference Call Scheduled for 5:00 p.m. ET --

SAN DIEGO, July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows:

Date:	Thursday, August 4, 2022
Time:	5:00 pm. ET (2:00pm. PT)
Live call:	(800) 285-6670 (U.S. toll-free) or (713) 481-1320
Webcast (live and archived) and related slide presentation:	https://evofeminvestorroomcom/2022Q2Results or https://www.webcast-eqs.com/evofem20220804/en

Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call.

About Evofem Biosciences
Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. The Company expects to report top-line data this fall from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for two potential new indications – prevention of chlamydia and prevention of gonorrhea in women. Learn more at phexxi.com and evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com 
(917) 673-5775

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2022-results-and-provide-corporate-update-on-thursday-august-4-2022-301595132.html

SOURCE Evofem Biosciences, Inc.

FAQ

What date is Evofem Biosciences holding its second quarter 2022 earnings call?

Evofem Biosciences is holding its second quarter 2022 earnings call on August 4, 2022.

What time is the Evofem Biosciences conference call scheduled for?

The Evofem Biosciences conference call is scheduled for 5:00 p.m. ET.

How can I join the Evofem Biosciences conference call?

You can join the Evofem Biosciences conference call by dialing (800) 285-6670 (U.S. toll-free) or (713) 481-1320 for international participants.

Where can I find the webcast for the Evofem Biosciences earnings call?

The webcast for the Evofem Biosciences earnings call can be found at https://evofeminvestorroom.com/2022Q2Results.

What product is Evofem Biosciences known for?

Evofem Biosciences is known for its FDA-approved product Phexxi®, which is a hormone-free contraceptive.

When does Evofem Biosciences expect to report clinical trial data?

Evofem Biosciences expects to report top-line data from its Phase 3 EVOGUARD clinical trial this fall.